KT-253
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients With High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid Tumors
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 70 patients (estimated)
- Sponsors
- Kymera Therapeutics, Inc.
- Tags
- MDM2 Inhibitor
- Trial Type
- Treatment
- Last Update
- 5 days ago
- SparkCures ID
- 1828
- NCT Identifier
- NCT05775406
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.